独立董事候选人声明与承诺 本人曾伟民，已充分了解并同意由提名人宁夏中科生物科技股份有限公司董 事会提名为宁夏中科生物科技股份有限公司第十届董事会独立董事候选人。本人 公开声明，本人具备独立董事任职资格，保证不存在任何影响本人担任宁夏中科 生物科技股份有限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有 5 年以上法律、经济、会计、财务、管理或者其他履 行独立董事职责所必需的工作经验。本人尚未参加培训未取得上海证券交易所下 发的独立董事资格证书。本人承诺在本次提名后，参加上海证券交易所举办的最 近一期独立董事资格培训并取得独立董事资格证书。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离） ...

提名人宁夏中科生物科技股份有限公司董事会，现提名赵向阳先生、刘辉先 生、曾伟民先生为宁夏中科生物科技股份有限公司第十届董事会独立董事候选 人，并已充分了解被提名人职业、学历、职称、详细的工作经历、全部兼职、有 无重大失信等不良记录等情况。被提名人已书面同意出任宁夏中科生物科技股份 有限公司第十届董事会独立董事候选人。提名人认为，被提名人具备独立董事任 职资格，与宁夏中科生物科技股份有限公司之间不存在任何影响其独立性的关 系，具体声明并承诺如下： 一、被提名人赵向阳先生、刘辉先生、曾伟民先生具备上市公司运作的基本 知识，熟悉相关法律、行政法规、规章及其他规范性文件，具有 5 年以上法律、 经济、会计、财务、管理或者其他履行独立董事职责所必需的工作经验。被提名 人赵向阳已经参加培训并取得上海证券交易所下发的独立董事资格证书。被提名 人刘辉、曾伟民尚未参加培训未取得上海证券交易所下发的独立董事资格证书， 并承诺在本次提名后，参加上海证券交易所举办的最近一期独立董事资格培训并 取得独立董事资格证书。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； ...

证券代码：600165 证券简称：*ST 宁科 公告编号：2025-131 宁夏中科生物科技股份有限公司 一、 召开会议的基本情况 至2025 年 12 月 29 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 1 股东会召开日期：2025年12月29日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (一) 股东会类型和届次 2025年第五次临时股东会 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 29 日14 点 30 分 召开地点：宁夏中科生物科技股份有限公司会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 29 日 (六) 融资融券、转融通、约定购回业务账户和 ...

宁夏中科生物科技股份有限公司 第九届董事会第四十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次董事会应到董事 7 名，实到董事 7 名。 ● 本次董事会共五项议案，经审议全部获得通过。 一、董事会会议召开情况 证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-128 （一）本次董事会召开符合有关法律、行政法规、部门规章、规范性文件和 《宁夏中科生物科技股份有限公司章程》的规定。 （二）本次董事会通知于 2025 年 12 月 8 日以微信和电子邮件方式送达，会 议材料于 2025 年 12 月 10 日以电子邮件方式送达。 （三）本次董事会于 2025 年 12 月 11 日上午 10:00 以现场结合通讯方式召 开。 （四）本次董事会应到董事 7 名，实到董事 7 名。 （五）本次董事会由董事长符杰先生主持，全体高级管理人员列席了会议。 二、董事会会议审议情况 与会董事对提交本次会议的五项议案进行了认真审议，表决情况如下： （一）审议《关于续聘信永中和会计师事 ...

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-127 宁夏中科生物科技股份有限公司 关于收到重整投资人全部重整投资款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁夏中科生物科技股份有限公司（以下简称：公司）于近日收到管理人的通 知，管理人账户已收到全体重整投资人支付的全部重整投资款。现将相关情况公 告如下： （一）终止上市的风险 公司被法院裁定终止重整程序，进入重整计划执行阶段。根据《中华人民共 和国企业破产法》的相关规定，在重整计划执行期间，如公司不执行或不能执行 重整计划，将存在被法院宣告破产的风险。如果公司被宣告破产，公司将被实施 破产清算，根据《上海证券交易所股票上市规则》第 9.4.15 条的规定，公司股票 将面临被终止上市的风险。 1 （二）其他风险 一、重整投资协议的签署情况 湖南醇投实业发展有限公司、湖南新合新生物医药有限公司与公司、公司临 时管理人签署了《预重整投资协议（产业投资人）》，相关财务投资人与公司、 公司临时管理人签署了《预重整投资协议（财务投资人）》，具体内容 ...

格隆汇12月10日丨ST宁科(600165.SH)公布，公司于近日收到管理人的通知，管理人账户已收到全体重 整投资人支付的全部重整投资款。截至本公告披露日，管理人账户已收到全体重整投资人支付的全部重 整投资款，合计人民币12.41亿元。全体重整投资人已支付完毕全部的重整投资款。 ...

Core Viewpoint - Ningxia Zhongke Biological announced that it has received a total of 1.241 billion yuan from all restructuring investors, which is crucial for its financial recovery [1] Group 1: Financial Developments - The company has received the full amount of restructuring investment from investors, totaling 1.241 billion yuan [1] - Prior to this, Hunan Chuntou and other industrial and financial investors signed pre-restructuring investment agreements with the company and the temporary management [1] Group 2: Risks and Challenges - The company faces the risk of delisting if it fails to execute or cannot execute the restructuring plan, which could lead to bankruptcy and liquidation [1] - There is a possibility that the investment agreements may be terminated or rescinded, posing additional risks to the company [1] - Subsidiaries Zhongke New Materials and Hengli Guotai also face bankruptcy risks if they do not execute the restructuring plan [1]

Core Viewpoint - *ST Ningke has finalized the details of its capital reserve stock increase plan, which involves a total of 931 million shares being issued, significantly increasing its total share capital from 685 million to 1.616 billion shares [4][11]. Group 1: Stock Increase Details - The stock increase consists of 883 million shares for introducing restructuring investors, raising approximately 1.241 billion yuan in cash, and 48 million shares for debt compensation, amounting to about 576 million yuan [2][13]. - The new controlling shareholder, Hunan Xinhai New Biological Pharmaceutical Co., Ltd., will hold a 22.10% stake in the company post-increase [2][10]. Group 2: Stock Trading Information - The stock will be suspended for one trading day on the registration date, December 10, and will resume trading on December 11, with an ex-rights reference price set at 2.84 yuan per share [5][7]. - The average price for the capital reserve stock increase is calculated to be 1.95 yuan per share, leading to a downward adjustment of the opening reference price on December 11 [7]. Group 3: Restructuring and Financial Health - The restructuring plan includes a commitment from the investors for a lock-up period of 36 months for industrial investors and 12 months for financial investors [8]. - As of the end of 2023, Hunan Xinhai New has total assets of 3.512 billion yuan and revenue of 1.236 billion yuan, focusing on the research, production, and sales of steroid intermediates and raw materials [14].

Group 1 - Rhein Biotech and Jia Mei Packaging's controlling shareholders are planning changes in company control, with trading suspension starting from December 10, 2025, for Rhein Biotech expected to last no more than 10 trading days and for Jia Mei Packaging no more than 2 trading days [1][2] - Rhein Biotech intends to acquire at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a combination of issuing shares and cash payment, which will make Beijing Jinkangpu a subsidiary included in the consolidated financial statements [1] - Jia Mei Packaging's controlling shareholder is also in discussions regarding a potential change in control, with specific transaction details still under negotiation [2] Group 2 - Haiguang Information has terminated its plan to merge with Zhongke Shuguang through a share exchange, as approved in a board meeting on December 9, 2025 [3] - Huatai Medical plans to repurchase shares with a total amount not less than RMB 200 million and not exceeding RMB 250 million, with a repurchase price cap of RMB 315 per share [4] - Songcheng Performing Arts and Jingu Co., Ltd. also announced share repurchase plans, with Songcheng aiming for a total of RMB 100 million to RMB 200 million and Jingu targeting RMB 30 million to RMB 60 million [4] Group 3 - Xiamen Airport is planning to acquire 100% of the shares of Zhaoxiang Technology, a wholly-owned subsidiary of its controlling shareholder, Xiamen Xiangye Group [5] - Borui Communication intends to acquire 51% of Meijing Technology from related parties for a total price of RMB 66.49 million [6] - Gu Ao Technology's actual controller is planning a change in control, with trading suspension starting from December 8, 2025, and expected to last no more than 3 trading days [6] Group 4 - ST Kevin's application to revoke the risk warning on its stock has been approved, with trading suspension for one day on December 10, 2025, and resuming trading on December 11, 2025 [6] - Huailun Crystal's stock will be suspended for one day starting December 10, 2025, due to false disclosures in its annual reports for 2021 and 2022 [7] - The stock of Jia Ao Environmental Protection will also be suspended for one day on December 10, 2025, due to an administrative penalty notice received from the regulatory authority [12] Group 5 - The company Yongmota plans to invest approximately RMB 400 million in a new project for magnesium-aluminum alloy components for the automotive and robotics industries [20] - ST Ningke is executing a capital reserve transfer plan to increase its share capital, with a total share increase from 684.88 million to 1.62 billion shares [21] - Yingpais plans to increase its shareholding through a combination of bank loans and self-funding, with a total investment of no less than RMB 60 million and no more than RMB 120 million [22]

Group 1 - The core point of the announcement is that *ST Ningke will implement a capital reserve transfer to increase its share capital, leading to a one-day suspension of trading on December 10, 2025, with resumption on December 11, 2025 [1] - As of the latest report, *ST Ningke has a market capitalization of 2.8 billion yuan [2] - The revenue composition for *ST Ningke in 2024 is as follows: 64.0% from the manufacturing of chemical raw materials and chemical products, 35.26% from the manufacturing of bio-based and starch-based new materials, and 0.74% from other businesses [1]